Yang, X., Kong, F., Qi, L., Lin, J., Yan, Q., Loong, J. H. C., . . . Liu, M. (2021). PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer.
Citación estilo ChicagoYang, Xiao-Dong, et al. "PARP Inhibitor Olaparib Overcomes Sorafenib Resistance Through Reshaping the Pluripotent Transcriptome in Hepatocellular Carcinoma." Mol Cancer 2021.
Cita MLAYang, Xiao-Dong, et al. "PARP Inhibitor Olaparib Overcomes Sorafenib Resistance Through Reshaping the Pluripotent Transcriptome in Hepatocellular Carcinoma." Mol Cancer 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.